Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
HCW Biologics Inc(HCWB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HCWB
11/13/2026: HCWB (1-star) is currently NOT-A-BUY. Pass it for now.
HCW Biologics is a clinical-stage biotechnology company developing novel fusion immunotherapeutics to address inflammaging, including autoimmune diseases and cancer. While the company has a proprietary platform that provides a strong pipeline of innovative candidates and potential manufacturing reagents, it currently faces significant financial pressure and generates negligible revenue. Its investment story centers on the success of its lead clinical programs and the potential to monetize its technology through partnerships. Key risks include heavy reliance on dilutive capital, intense industry competition, and inherent clinical trial execution hurdles. The stock is a speculative, high-risk play best suited for investors with a deep understanding of early-stage biotech, rather than dividend or low-risk investors.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is at a very early, pre-commercial stage with high binary risk and inconsistent revenue. |
| Momentum investor | Weak fit | The stock often faces high volatility and structural downward pressure related to financing needs. |
| Value investor | Weak fit | The company's lack of earnings and significant cash burn make traditional valuation metrics difficult to apply. |
| Dividend investor | Weak fit | HCW Biologics does not pay dividends and focuses entirely on R&D investment. |
| Low-risk investor | Weak fit | The speculative nature, high price volatility, and significant execution risk make this unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is subject to large, rapid swings based on clinical news and frequent dilutive financing. |
| Valuation risk | High | As a loss-making clinical firm, its valuation is disconnected from standard earnings-based metrics. |
| Competition risk (Biotechnology/Oncology) | High | The company faces immense pressure from much larger, better-funded incumbents in the competitive immunotherapy market. |
| Business quality | High | The business relies on future scientific breakthroughs and external partnerships to prove its viability. |
| Dividend income | Low / none | There is no potential for dividend income in the foreseeable future. |
| Execution risk | High | Success depends entirely on the company's ability to navigate complex clinical trials and regulatory approval processes. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.73M USD | Price to earnings Ratio - | 1Y Target Price 48 |
Price to earnings Ratio - | 1Y Target Price 48 | ||
Volume (30-day avg) 119.7K shares | Beta 2.27 | 52 Weeks Range 0.76 - 23.94 | Updated Date 11/14/2026 |
52 Weeks Range 0.76 - 23.94 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.84 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -18.95% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Licensing & Partnerships | Upfront payments, milestone payments, and potential royalties from licensing its proprietary compounds to other biotech/pharma firms. | The company makes money primarily by selling or licensing the rights to its drug candidates or technology to other companies. |
| Reagent Program | Future sales of proprietary fusion protein compounds as manufacturing reagents for cell therapies. | The company is seeking to commercialize its compounds as tools for others to use in making complex cancer therapies. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7.61M | Price to Sales(TTM) 0.26 |
Enterprise Value 7.61M | Price to Sales(TTM) 0.26 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA -3.63 | Shares Outstanding 2.24M | Shares Floating 1.68M |
Shares Outstanding 2.24M | Shares Floating 1.68M | ||
Percent Insiders 7.98 | Percent Institutions 8.37 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.